our $10.00 target price. 18 EFTA00810593 BROOKLINE CAPITAL MARKETS A Division of CIM Securities Veru, Inc. (VEAL)) / April 05, 2018 Figure 3: Veru BioPharma Sum of Parts Valuation TAMSULOSIN DRS(XR Pipeline premium 25% Sum of Parts Value (SM) NPV per share Expected Launch Probability of Peak Market Peak Sales Probabili